Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
78.4M
-
Number of holders
-
103
-
Total 13F shares, excl. options
-
40.8M
-
Shares change
-
-497K
-
Total reported value, excl. options
-
$704M
-
Value change
-
-$8.66M
-
Number of buys
-
56
-
Number of sells
-
-32
-
Price
-
$17.27
Significant Holders of Replimune Group, Inc. - COMMON STOCK (REPL) as of Q3 2022
111 filings reported holding REPL - Replimune Group, Inc. - COMMON STOCK as of Q3 2022.
Replimune Group, Inc. - COMMON STOCK (REPL) has 103 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40.8M shares
of 78.4M outstanding shares and own 52.03% of the company stock.
Largest 10 shareholders include Omega Fund Management, LLC (4.29M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.17M shares), BAKER BROS. ADVISORS LP (3.89M shares), Redmile Group, LLC (3.65M shares), Atlas Venture Life Science Advisors, LLC (3.11M shares), BlackRock Inc. (2.77M shares), VANGUARD GROUP INC (1.85M shares), STATE STREET CORP (1.45M shares), T. Rowe Price Investment Management, Inc. (1.23M shares), and EMERALD ADVISERS, LLC (1.14M shares).
This table shows the top 103 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.